药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201922721213114.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文Saxenda处方资料(仅供参考)
【英文名称】Saxenda
【适用证】
Saxenda是一种胰高血糖素样肽-1(GLP-1)受体激动剂,作为低热量饮食的辅助手段,增加了成人患者慢性体重管理的体力活动,其初始体重指数(BMI)为
30 kg / m或更高(肥胖)(1)或
在存在至少一种体重相关的共患病症(例如,高血压,2型糖尿病或血脂异常)的情况下,27kg / m或更高(超重)(1)。
使用限制:
Saxenda不适用于治疗2型糖尿病(1)。
Saxenda不应与任何其他GLP-1受体激动剂(1)联合使用。
Saxenda不应与胰岛素一起使用(1,5.4)。
与其他产品共同用于减肥的安全性和有效性尚未确定(1)。
【禁忌症】
甲状腺髓样癌或多发性内分泌2型(4,5.1)的个人或家族史。
对利拉鲁肽或任何产品成分过敏(4,5.7)。
怀孕(4,8.1)。
【用法用量】
Saxenda的推荐剂量为每日3毫克。 在一天中的任何时间管理,而不考虑进餐时间(2)。
每天0.6毫克,持续一周。 每周一次,增加剂量,直至达到3毫克的剂量(2)。
在腹部,大腿或上臂皮下注射(2)。
注射部位和时间可以在没有剂量调整的情况下改变(2)
【INDICATIONS AND USAGE】
Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of
30 kg/m or greater (obese) (1) or
27 kg/m or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia) (1).
Limitations of Use:
Saxenda is not indicated for the treatment of type 2 diabetes (1).
Saxenda should not be used in combination with any other GLP-1 receptor agonist (1).
Saxenda should not be used with insulin (1, 5.4).
The safety and efficacy of coadministration with other products for weight loss have not been established (1).
【DOSAGE AND ADMINISTRATION】
Recommended dose of Saxenda is 3 mg daily. Administer at any time of day, without regard to the timing of meals(2).
Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached (2).
Inject subcutaneously in the abdomen, thigh or upper arm (2).
The injection site and timing can be changed without dose adjustment (2
【CONTRAINDICATIONS】
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (4, 5.1).
Hypersensitivity to liraglutide or any product components (4, 5.7).
Pregnancy (4, 8.1).
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201922721213114.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |